PHR241018C30000
- 0.05
- 0.000.00%
Phreesia Newsroom
Down -10.25% in 4 Weeks, Here's Why Phreesia (PHR) Looks Ripe for a Turnaround
Phreesia Joins the Network Advertising Initiative as a Member, Demonstrating Ongoing Commitment to Industry-Leading Privacy Practices
Phreesia and Ad Council Partnership Yields High Patient Engagement in 3 Mental Health Awareness Campaigns
Phreesia Rises After New Contract
Express News | Phreesia: Contract With CMS Innovation Center (Cmmi) for Use of Patient Activation Measure® (PAM) Has Been Renewed Through 2029
Phreesia Secures New Contract With CMS as Report Shows Gains in Patient Activation in First Year of Kidney Care Choices (KCC) Model
RBC Capital Maintains Phreesia(PHR.US) With Hold Rating, Maintains Target Price $23
Is Phreesia (NYSE:PHR) A Risky Investment?
巴克莱银行维持Phreesia(PHR.US)买入评级，维持目标价29美元
Barclays analyst Stephanie Davis maintains $Phreesia(PHR.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 43.4% and a total
Phreesia (PHR) Gets a Buy From Barclays
Phreesia Exec Sells Over $2,300 in Stock Amid Mandatory Policy
New Research Shows Point-of-Care Patient Outreach Supports Vaccine Confidence and Adoption
CDC Awards Grant to NAFC, Phreesia and Health.Equity.Outcomes. to Tackle Public Health Challenge of Urinary Incontinence
Phreesia (PHR) Improves Healthcare Outcomes and Expects Growing Clientele
JP Morgan Maintains Overweight on Phreesia, Raises Price Target to $28
Phreesia Analyst Ratings
J.P. Morgan Maintains Phreesia(PHR.US) With Buy Rating, Raises Target Price to $28
J.P. Morgan analyst Anne Samuel maintains $Phreesia(PHR.US)$ with a buy rating, and adjusts the target price from $27 to $28.According to TipRanks data, the analyst has a success rate of 51.0% and a
Truist Financial Maintains Phreesia(PHR.US) With Buy Rating, Announces Target Price $31
Truist Financial analyst Jailendra Singh maintains $Phreesia(PHR.US)$ with a buy rating, and sets the target price at $31.According to TipRanks data, the analyst has a success rate of 34.0% and a
Baird Maintains Phreesia(PHR.US) With Buy Rating, Raises Target Price to $34
Baird analyst Joseph Vruwink maintains $Phreesia(PHR.US)$ with a buy rating, and adjusts the target price from $31 to $34.According to TipRanks data, the analyst has a success rate of 63.0% and a
A Quick Look at Today's Ratings for Phreesia(PHR.US), With a Forecast Between $30 to $34
On Sep 06, major Wall Street analysts update their ratings for $Phreesia(PHR.US)$, with price targets ranging from $30 to $34.Baird analyst Joseph Vruwink maintains with a buy rating, and adjusts